3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis

Main Article Content

Richard B Warren
Kristian Reich
Eric L Simpson
Richard Langley
Antonio Costanzo
Hidehisa Saeki
Peter Almgren
Emilia Vacko
Melinda Gooderham
Mette Deleuran
Juan Francisco Silvestre
Stefan Weidinger
Andrew Blauvelt

Keywords

tralokinumab, atopic dermatitis, efficacy

References

1. Weidinger S, Novak N. Lancet. 2016;387(10023):1109-1122

2. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36(9):1409-1431

3. de Bruin-Weller M, et al. Acta Derm Venereol 2021; 101: adv00402

4. Blauvelt A, et al. Poster presented at: American Academy of Dermatology Annual Meeting; March 25-29, 2022, Boston, MA

5. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3

6. Simpson E, et al. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) Conference; December 13–14, 2020, Virtual

7. Chuang-Stein C. Pharm Stat 2011; 10:3–7

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>